Sneezing News and Research

RSS

Schering-Plough announces European approval of new formulations of AERIUS (Desloratadine)

European Commission approves AERIUS Tablets (2.5 mg and 5 mg) and AERIUS Oral Solution (0.5 mg per 1ml).

30 Apr 2007

Employers can blame hay fever for the loss of millions of hours of work productivity this spring

A new study of nearly 600 people with hay fever symptoms, including sneezing, watery eyes and runny and itchy noses, found that workers missed an hour of work per week during peak hay fever season.

27 Apr 2007

Prostate cancer treatments impact on quality of life

A rigorous, long-term study of quality of life in patients who underwent one of the three most common treatments for prostate cancer found that each affected men's lives in different ways.

24 Apr 2007

Long-term study of prostate cancer treatments

A rigorous, long-term study of quality of life in patients who underwent one of the three most common treatments for prostate cancer found that each affected men's lives in different ways.

24 Apr 2007

Ranbaxy receives U.S. approval to market Loratadine Antihistamine tablets

Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.

15 Apr 2007

GlaxoSmithKline files European meningococcal conjugate vaccine

GlaxoSmithKline has announced the submission of a regulatory file to European Medicines Agency (EMEA) under Article 58 for the combination vaccine candidate Globorix (diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Neisseria meningitides serogroups A and C).

1 Apr 2007

15,595 meningitis cases this season in Africa

Two months into the dry season in the African "Meningitis Belt", 15,595 cases including 1,670 deaths have been reported to the World Health Organization (WHO) from four countries: Burkina Faso, the Democratic Republic of the Congo, Sudan and Uganda.

19 Mar 2007

Different treatments may be needed for chronic asthma, depending on whether it results from allergies or lung infections

Researchers have now identified a particular gene that influences how severe a M. pneumoniae infection may be, which in turn suggests that a different strategy might be needed for treating asthma resulting from this and similar lung infections rather than allergies.

31 Jan 2007

A plasminogen-activating protease specifically controls the development of primary pneumonic plague

The deadly attack of the bacterium that causes pneumonic plague is significantly slowed when it can't make use of a key protein, scientists at Washington University School of Medicine in St. Louis report in Science.

28 Jan 2007

FDA approves Omnaris, new hay fever drug

The U.S. Food and Drug Administration (FDA) has announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.

23 Oct 2006

Tuberculosis fourfold the risk for Celiac sufferers

Swedish researchers are suggesting that people with celiac disease, also known as gluten intolerance, have an increased risk of developing tuberculosis (TB).

17 Oct 2006

High rates of pertussis found in States with easy immunization exemptions

States that easily permit parents to opt out of vaccinating their children for nonmedical reasons are at increased risk of pertussis (whooping cough), according to a new study from researchers with the Johns Hopkins Bloomberg School of Public Health, the University of Florida and the Centers for Disease Control and Prevention (CDC).

10 Oct 2006

Six shot course gives two year protection from hay fever

An experimental vaccine is promising to prevent hay fever symptoms for at least two years, and this is after just six injections.

5 Oct 2006

Extremely virulent, drug resistant strain of TB running wild in South Africa

It was 18 months ago when doctors in South Africa who were treating HIV/AIDS patients first raised the alarm that an untreatable form of tuberculosis (TB) was circulating.

18 Sep 2006

Uroplasty receives FDA approvable letter for treatment of female stress urinary incontinence

Uroplasty, Inc. has announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) relating to its pre-market approval (PMA) application for Macroplastique Implants for the treatment of female stress urinary incontinence (SUI).

14 Sep 2006